Immune Therapy Opportunities in Ovarian Cancer.
Détails
ID Serval
serval:BIB_71D55C2B15BF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immune Therapy Opportunities in Ovarian Cancer.
Périodique
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
ISSN
1548-8756 (Electronic)
ISSN-L
1548-8748
Statut éditorial
Publié
Date de publication
05/2020
Peer-reviewed
Oui
Volume
40
Pages
1-13
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Immunotherapy has emerged as a highly promising approach in the treatment of epithelial ovarian cancer (EOC). Immune checkpoint blockade (ICB) therapy, PARP inhibitors (PARPis), neoantigen vaccines, and personalized T-cell therapy have been associated with encouraging clinical activity in a small subset of patients. To increase the proportion of patients who are likely to derive benefit, it will be important not only to generate sufficient numbers of antitumor T cells but also to overcome multiple inhibitory networks in the ovarian tumor microenvironment (TME). Therefore, a major direction is to develop biomarkers that would predict responsiveness to different types of immunotherapies and allow treatment selection based on the results. Moreover, such biomarkers would allow rational combination of immunotherapies while minimizing toxicities. In this review, we provide progress on immune therapies and future directions for maximally exploiting immune-based strategies for the treatment of ovarian cancer.
Pubmed
Création de la notice
14/06/2020 21:16
Dernière modification de la notice
23/01/2021 7:21